Literature DB >> 25326930

Healthcare utilization and costs in persons with insomnia in a managed care population.

Louise H Anderson, Robin R Whitebird, Jennifer Schultz, Charlene E McEvoy, Mary Jo Kreitzer, Cynthia R Gross.   

Abstract

OBJECTIVES: To better understand the direct costs of insomnia. Our study aimed to compare healthcare costs and utilization of patients diagnosed with insomnia who received care in a managed care organization with a set of matched controls.
DESIGN: Our observational, retrospective cohort study compared 7647 adults with an insomnia diagnosis with an equally sized matched cohort of health plan members without an insomnia diagnosis between 2003 and 2006. We also compared a subset of patients diagnosed with and treated for insomnia with those diagnosed with insomnia but not treated.
SETTING: A large Midwestern health plan with more than 600,000 members.
RESULTS: Multivariate analysis was used to estimate the association between insomnia diagnosis and costs, controlling for covariates, in the baseline and follow-up periods. Although we cannot conclude a causal relationship between insomnia and healthcare costs, our analysis found that insomnia diagnosis was associated with 26% higher costs in the baseline and 46% in the 12 months after diagnosis. When comorbidities were recognized, the insomnia cohort had 80% higher costs, on average, than the matched control cohort.
CONCLUSIONS: These outcomes suggest the need to look beyond the direct cost of insomnia to how its interaction with comorbid conditions drives healthcare cost and utilization.

Entities:  

Mesh:

Year:  2014        PMID: 25326930

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  11 in total

1.  Telephone interventions for co-morbid insomnia and osteoarthritis pain: The OsteoArthritis and Therapy for Sleep (OATS) randomized trial design.

Authors:  Susan M McCurry; Michael Von Korff; Charles M Morin; Amy Cunningham; Kenneth C Pike; Manu Thakral; Robert Wellman; Kai Yeung; Weiwei Zhu; Michael V Vitiello
Journal:  Contemp Clin Trials       Date:  2019-10-13       Impact factor: 2.226

2.  Daytime Sleep Disturbance in Night Shift Work and the Role of PERIOD3.

Authors:  Philip Cheng; Gabriel Tallent; Helen J Burgess; Kieulinh Michelle Tran; Thomas Roth; Christopher L Drake
Journal:  J Clin Sleep Med       Date:  2018-03-15       Impact factor: 4.062

3.  Cost-effectiveness of telephone cognitive behavioral therapy for osteoarthritis-related insomnia.

Authors:  Kai Yeung; Weiwei Zhu; Susan M McCurry; Michael Von Korff; Robert Wellman; Charles M Morin; Michael V Vitiello
Journal:  J Am Geriatr Soc       Date:  2021-10-11       Impact factor: 5.562

4.  Psychometric Validation of the Insomnia Severity Index in Adults with Sickle Cell Disease.

Authors:  Gyasi Moscou-Jackson; Jerilyn Allen; Michael T Smith; Carlton Haywood
Journal:  J Health Care Poor Underserved       Date:  2016-02

5.  A population health approach to insomnia using internet-based cognitive behavioral therapy for insomnia.

Authors:  Stephen F Derose; Emily Rozema; Aiyu Chen; Ernest Shen; Dennis Hwang; Prasanth Manthena
Journal:  J Clin Sleep Med       Date:  2021-08-01       Impact factor: 4.324

6.  What do hypnotics cost hospitals and healthcare?

Authors:  Daniel F Kripke
Journal:  F1000Res       Date:  2017-04-21

7.  Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2.

Authors:  Mikko Kärppä; Jane Yardley; Kate Pinner; Gleb Filippov; Gary Zammit; Margaret Moline; Carlos Perdomo; Yuichi Inoue; Kohei Ishikawa; Naoki Kubota
Journal:  Sleep       Date:  2020-09-14       Impact factor: 5.849

8.  Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant.

Authors:  Hrishikesh P Kale; Zaina P Qureshi; Ruchit Shah; Rezaul Khandker; Marc Botteman; Weilin Meng; Ruth Benca
Journal:  Adv Ther       Date:  2021-08-31       Impact factor: 3.845

9.  Self-reported poor sleep on multiple dimensions is associated with higher total health care costs in older men.

Authors:  John T Schousboe; Allyson M Kats; Katie L Stone; Lisa Langsetmo; Tien N Vo; Terri L Blackwell; Daniel J Buysse; Sonia Ancoli-Israel; Kristine E Ensrud
Journal:  Sleep       Date:  2020-10-13       Impact factor: 5.849

10.  Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant.

Authors:  Ishani Landry; Jagadeesh Aluri; Nancy Hall; Gleb Filippov; Satish Dayal; Margaret Moline; Larisa Reyderman
Journal:  Pharmacol Res Perspect       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.